JP2022532430A - Ｎｋ細胞指向性キメラタンパク質 - Google Patents

Ｎｋ細胞指向性キメラタンパク質 Download PDF

Info

Publication number
JP2022532430A
JP2022532430A JP2021568608A JP2021568608A JP2022532430A JP 2022532430 A JP2022532430 A JP 2022532430A JP 2021568608 A JP2021568608 A JP 2021568608A JP 2021568608 A JP2021568608 A JP 2021568608A JP 2022532430 A JP2022532430 A JP 2022532430A
Authority
JP
Japan
Prior art keywords
chimeric protein
domain
nkg2a
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532430A5 (https=
Inventor
シュライバー、テイラー
シュプトライン、ケイシー
フロム、ジョージ
シルヴァ、スレシュ デ
Original Assignee
シャタック ラボ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャタック ラボ，インコーポレイテッド filed Critical シャタック ラボ，インコーポレイテッド
Publication of JP2022532430A publication Critical patent/JP2022532430A/ja
Publication of JP2022532430A5 publication Critical patent/JP2022532430A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021568608A 2019-05-16 2020-05-15 Ｎｋ細胞指向性キメラタンパク質 Pending JP2022532430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848915P 2019-05-16 2019-05-16
US62/848,915 2019-05-16
PCT/US2020/033169 WO2020232365A1 (en) 2019-05-16 2020-05-15 Nk cell-directed chimeric proteins

Publications (2)

Publication Number Publication Date
JP2022532430A true JP2022532430A (ja) 2022-07-14
JP2022532430A5 JP2022532430A5 (https=) 2023-05-23

Family

ID=73289381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568608A Pending JP2022532430A (ja) 2019-05-16 2020-05-15 Ｎｋ細胞指向性キメラタンパク質

Country Status (7)

Country Link
US (2) US20200399344A1 (https=)
EP (1) EP3969058A4 (https=)
JP (1) JP2022532430A (https=)
CN (1) CN114126663A (https=)
AU (1) AU2020276296A1 (https=)
CA (1) CA3140055A1 (https=)
WO (1) WO2020232365A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024524301A (ja) * 2021-07-02 2024-07-05 ラエクナ セラピューティクス シャンハイ カンパニー リミテッド 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用
CN114853905B (zh) * 2022-04-14 2022-11-22 呈诺再生医学科技(珠海横琴新区)有限公司 一种基因修饰nk细胞与抗体联合使用治疗肿瘤方案
WO2024073513A2 (en) * 2022-09-27 2024-04-04 Affini-T Therapeutics, Inc. Chimeric receptors comprising interleukin 7 receptor (il7r) domains
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281035A1 (en) * 2006-06-22 2009-11-12 Novo Nordisk A/S Soluble Heterodimeric Receptors and Uses Thereof
US20170008951A1 (en) * 2012-01-27 2017-01-12 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
US20180134766A1 (en) * 2016-09-27 2018-05-17 Epicentrx, Inc. Immunomodulatory fusion proteins
US20180326008A1 (en) * 2015-10-01 2018-11-15 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281035A1 (en) * 2006-06-22 2009-11-12 Novo Nordisk A/S Soluble Heterodimeric Receptors and Uses Thereof
US20170008951A1 (en) * 2012-01-27 2017-01-12 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
US20180326008A1 (en) * 2015-10-01 2018-11-15 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
US20180134766A1 (en) * 2016-09-27 2018-05-17 Epicentrx, Inc. Immunomodulatory fusion proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GALIT EISENBERG ET AL.: "Soluble SLAMF6 Receptor Induces Strong CD8 + T-cell Effector Function and Improves Anti-Melanoma Act", CANCER IMMUNOLOGY RESEARCH, vol. 6, no. 2, JPN6024022614, 1 February 2018 (2018-02-01), pages 127 - 138, XP055497033, ISSN: 0005344056, DOI: 10.1158/2326-6066.CIR-17-0383 *
PADUA ET AL.: "Roles of TGFI3 in metastasis", CELL RESEARCH, vol. 19, no. 1, JPN6024022613, 2 December 2008 (2008-12-02), pages 89 - 102, XP009531804, ISSN: 0005344057, DOI: 10.1038/cr.2008.316 *

Also Published As

Publication number Publication date
EP3969058A1 (en) 2022-03-23
CN114126663A (zh) 2022-03-01
CA3140055A1 (en) 2020-11-19
US20200399344A1 (en) 2020-12-24
EP3969058A4 (en) 2023-06-28
US20230045794A1 (en) 2023-02-16
WO2020232365A1 (en) 2020-11-19
AU2020276296A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
US20230045794A1 (en) Nk cell-directed chimeric proteins
JP2022511286A (ja) Ｓｉｒｐアルファ系キメラタンパク質を含む併用療法
JP7121029B2 (ja) Ｃｓｆ１ｒベースのキメラタンパク質
WO2021122866A1 (en) Bifunctional molecules comprising an il-7 variant
US20200071380A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
CN113747947A (zh) 组合疗法
JP2023071979A (ja) Ｖｓｉｇ８ベースのキメラタンパク質
JP2022512540A (ja) Ｆｌｔ３ｌ系キメラタンパク質
EP4077364A1 (en) Bifunctional molecules comprising an il-7 variant
US20240141014A1 (en) Mutant pd-1 extracellular domains
US20240299492A1 (en) Combination therapies with sirp alpha-based chimeric proteins
JP2022512539A (ja) 併用療法
CA3237449A1 (en) Sirp1a - and cd40l-based chimeric proteins
WO2022187583A1 (en) Combination therapies with tim-3-based chimeric proteins
JP2022503621A (ja) Ｔｉｍ－３系キメラタンパク質を含む併用療法
WO2024123890A1 (en) Methods of using light-based chimeric proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203